Key facts
- It has raised $8.6M across 1 recorded rounds; the latest was Seed Round ($4.8M) in Jul 2025.
- Notable investors include Brunnur Ventures, Omega ehf, Silfurberg (Reykjavík).
- Axelyf has filed 1 Form D with the SEC, most recently Aug 2025 ($4.8M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Axelyf
Funding rounds
1 roundsAbout Axelyf
Operator of a drug development company intended for metabolic diseases. The company offers astaxanthin material that originates from algae culture and ends as a proprietary prodrug with optimized oral bioavailability and distribution properties in the body, enabling patients to enhance their health and promote well-being.
- Sector
- Healthcare
- HQ
- Brookline, MA, United States
- Founded
- 2022
- Employees
- 10
- Website
- axelyf.com/
- Ownership
- Privately Held (backing)
Axelyf doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axelyf shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axelyf in its N-PORT filings yet. We sweep new filings monthly.